User profiles for Markus Maeurer

Markus Maeurer

Champalimaud Foundation, Lisbon Portugal and I Medical Clinical, University of Mainz …
Verified email at fundacaochampalimaud.pt
Cited by 21778

[HTML][HTML] Single-cell landscape of immunological responses in patients with COVID-19

…, TJ Jiang, M Shi, Y Zhang, A Zumla, M Maeurer… - Nature …, 2020 - nature.com
In coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection, the relationship between disease severity and the host …

Antigen-processing machinery breakdown and tumor growth

B Seliger, MJ Maeurer, S Ferrone - Immunology today, 2000 - cell.com
Defects in the major histocompatibility complex (MHC) class I antigen-processing machinery
(APM) have been described in tumors of different histology. Murine data suggest that …

[HTML][HTML] Immunological and inflammatory profiles in mild and severe cases of COVID-19

…, P Zhao, M Shi, C Agrati, G Ippolito, M Maeurer… - Nature …, 2020 - nature.com
COVID-19 is associated with 5.1% mortality. Although the virological, epidemiological, clinical,
and management outcome features of COVID-19 patients have been defined rapidly, the …

Reducing mortality from 2019-nCoV: host-directed therapies should be an option

A Zumla, DS Hui, EI Azhar, ZA Memish, M Maeurer - The Lancet, 2020 - thelancet.com
The number of confirmed cases of the 2019 novel coronavirus (2019-nCoV) reported to
WHO continues to rise worldwide. 1 As with two other WHO Blueprint priority coronaviruses, …

Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test

…, ZA Memish, GB Migliori, P Kim, M Maeurer… - The Lancet infectious …, 2013 - thelancet.com
Rapid progress has been made in the development of new diagnostic assays for tuberculosis
in recent years. New technologies have been developed and assessed, and are now …

[HTML][HTML] The WHO Global Tuberculosis 2021 Report–not so good news and turning the tide back to End TB

…, P Lungu, F Ntoumi, N Kumarasamy, M Maeurer… - International Journal of …, 2022 - Elsevier
Objective To review the data presented in the 2021 WHO global TB report and discuss the
current constraints in the global response. Introduction and methods The WHO global TB …

[HTML][HTML] Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial

…, D Zhang, Y Jiao, L Liu, C Zhou, M Maeurer… - Signal transduction and …, 2020 - nature.com
No effective drug treatments are available for coronavirus disease 2019 (COVID-19). Host-directed
therapies targeting the underlying aberrant immune responses leading to pulmonary …

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects

…, TD McHugh, M Schito, M Maeurer… - The Lancet infectious …, 2014 - thelancet.com
About 1·3 million people died of tuberculosis in 2012, despite availability of effective drug
treatment. Barriers to improvements in outcomes include long treatment duration (resulting in …

Emergence of new SARS-CoV-2 Variant of Concern Omicron (B. 1.1. 529)-highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of …

…, JJ Muyembe-Tamfum, EI Azhar, M Maeurer… - International Journal of …, 2022 - ijidonline.com
Nearly two years since the start of the SARS-CoV-2 pandemic, which has caused over 5
million deaths, the world continues to be on high COVID-19 alert. The World Health …

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of …

MJ Maeurer, SM Gollin, D Martin… - The Journal of …, 1996 - Am Soc Clin Investig
In the last few years, mutiple protein target antigens for immunorecognition by T cells have
been identified on human melanoma. How melanoma lesions escape from functional antigen-…